About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Optimized Peak VO2 in Predicting Advanced HF | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT05212649

Optimized Peak VO2 in Predicting Advanced HF

The ability and timely selection of severe heart failure (HF) patients for cardiac transplantation and advanced HF therapy is challenging. Peak VO2 by cardiopulmonary exercise test (CPET) was used for...

Lead sponsor: Chang Gung Memorial Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Chang Gung Memorial Hospital

Investigators retrospectively collected acute HF patients discharged alive from the hospital. Investigators divided participants into more-GDMT (≥2 kinds) and few-GDMT (\<2 kinds) groups and compared the prognostic significance of peak VO2 and HFSS for combined all-cause mortality and urgent cardiac transplantation.

Age

20 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•acute HF patients with reduced ejection fraction (left ventricular ejection fraction, LVEF \<=40%) and discharged alive from the hospital
•patients with age \>= 20 years of age
•patients who performed cardiopulmonary exercise test (CPET) within one month after discharge
•patients with serum B-type natriuretic peptide (BNP) level \>100 pg/mL.

Exclusion Criteria

•patients with estimated survival time \< 6 months
•patients who could not tolerate exercise test due to muscular-skeletal disorder or other reason
•patients who had severe valvular heart disease.

Related studies

MRI Assessment of Pulmonary Edema in Acute Heart Failure

NCT03999138 · Acute Heart Failure, Pulmonary Edema With Heart Failure

Biomarker Guided Discharge of Heart Failure Patients

NCT03103932 · Heart Failure; With Decompensation

RECRUITINGPhase 2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964 · Fontan Circulation, Single Ventricle Heart Disease, and more

Assessing Systemic Circulation and LV Performance in Adults

NCT04347655 · Heart Failure

RECRUITINGPhase 2

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011 · Heart Failure With Preserved Ejection Fraction

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 30, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment377

Start dateMay 2014

Last updatedAug 30, 2023

Condition

Heart Failure Morality Transplant; Failure, Heart

Locations shown

Chang Gung Memorial Hospital Heart Failure Center

Kaohsiung City

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 30, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions